Leukocyte immunoglobulin-like receptor 1 (LILRB1) is an inhibitory receptor that binds classical and non-classical MHC-I as well as UL18, a viral MHC-I homolog. LILRB1 is encoded within the leukocyte receptor complex and is widely expressed on immune cells. Two distinct promoters used differentially by lymphoid and myeloid cells were previously identified, but little is known regarding molecular regulation of each promoter or cell-type-specific usage. Here, we have investigated the transcriptional regulation of human LILRB1 focusing on elements that drive expression in NK cells. We found that while both the distal and proximal promoter regions are active in reporter plasmids in lymphoid and myeloid cells, the proximal promoter is used minimally to transcribe LILRB1 in NK cells compared with monocytes. We defined a 120-bp core region of transcriptional activity in the distal promoter that can bind several factors in NK cell nuclear extracts. Within this region, we investigated overlapping putative AP-1 sites. An inhibitor of JNK decreased LILRB1 transcript in a LILRB1 + NK cell line. Upon examining binding of specific AP-1 factors, we found JunD associated with the LILRB1 distal promoter. Finally, depletion of JunD led to a decrease in distal promoter transcript, indicating an activating role for JunD in regulation of LILRB1 transcription. This study presents the first description of regions/factors required for activity of the LILRB1 distal promoter, the first description of a role for JunD in NK cells and suggests a potential mechanism for dynamic regulation of LILRB1 by cytokines.
Introduction
The leukocyte immunoglobulin-like receptor (LILR) gene family is encoded within the highly polymorphic and densely packed leukocyte receptor complex on human chromosome 19 (1) (2) (3) . The receptor family includes both stimulatory and inhibitory receptors. The human locus encodes 11 functional family members that are broadly expressed within the immune system, several of which bind MHC-I molecules (1) (2) (3) . Interestingly, this receptor family is highly divergent between primates and mice. Where humans have five distinct genes encoding inhibitory LILRs, mice have only one, paired immunoglobulin-like receptor B (PIR-B) (reviewed in ref. 4) . How each inhibitory LILR relates to the single PIR-B is not known but PIR-B, LILRB1 and LILRB2 share MHC-I as an endogenous ligand (2, 5, 6) . PIR-B is expressed on most myeloid cells as well as B cells (7) . Mice lacking PIR-B exhibit some immune deviation such as enhanced T h 2 responses and higher susceptibility to salmonella, but overt autoimmunity has not been reported in these mice (5, 8, 9) . LILRB1 (also known as LIR-1, CD85j and ILT-2) is found on multiple types of myeloid cells and B cells, much like PIR-B, but also on subsets of T and NK cells (1, 2, 6, 10) . LILRB1 binds classical and non-classical MHC-I molecules to regulate immune cell function (2, (10) (11) (12) . In vitro, binding of LILRB1 can inhibit BCR signaling in B cells (2, 11) , FcR signaling in monocytes (10) as well as NK and T-cell activity (12) , presumably through ITIM-mediated signaling. LILRB1 is bound tightly by the MHC-I homolog, UL18, from human cytomegalovirus (HCMV) (6) and binds several types of bacteria as well (13) . The fact that pathogens subvert LILRB1 function suggests the importance of its role in immunity. Recently, polymorphism in LILRB1 was weakly associated with increased risk of developing HCMV disease in Caucasian HIV patients (14) as well as with developing rheumatoid arthritis in a Japanese population (15) .
LILRB1 has an interesting pattern of expression between different immune cell lineages. In PBMCs, LILRB1 is expressed on all monocytes and B cells, and subsets of T and NK cells. However, the amount of cell surface receptor detected per cell is much higher on monocytes than B cells (16) . LILRB1 expression on T cells is associated with terminally differentiated memory effector cells, being highly expressed within the CD56 + T-cell subset (17) . LILRB1 expression on NK cells varies between individuals in both its detection per cell and the number of cells that stain positive (2, 6, (18) (19) (20) (21) . In all likelihood, expression of LILRB1 in NK cells is regulated in a manner somewhat similar to the variegated expression of killer cell immunoglobulin-like receptors (KIRs) (22) , as not all NK clones express LILRB1 and we recently reported a correlation of LILRB1 genotype with expression on NK cells (18) . However, we have also found some changes in the receptor expression on NK and T cells over time in normal healthy subjects (21) , and perturbations in LILRB1 expression profiles on NK and T cells have been reported in several situations including post-transplant HCMV disease, HIV infection and first trimester pregnancy (23) (24) (25) (26) . In addition, we have observed that IL-2 and/or IL-15 cause some enhancement of surface expression of LILRB1 on NK and T cells in vitro as well as a potential role for IL-2 in regulating promoter activity in one NK-like cell line (21) .
In spite of the interesting pattern of expression and potential importance for tight regulation of the receptor's expression to maintain a balance in signals, there is little known regarding transcriptional regulation of the LILRB1 gene. The first study of the LILRB1 promoter characterized a region that is active in monocytes and is now known as the proximal promoter. This study defined a 160-bp core promoter ~500 bp upstream of the translational start codon that can be transactivated by the transcription factors PU.1 and Sp1 (27) . More recently, lymphoid cells were shown to use a distal promoter region located more than 13 kb upstream of the proximal promoter. The resulting longer transcript includes an additional exon that lacks a coding sequence (16) . However, the additional exon does contain multiple ATG sites that cause a translational 'stuttering' on this transcript as well as an ARE site and together these elements decrease the translational efficiency of the longer transcript relative to transcripts produced from the proximal promoter (16) . The difference in translational efficiency likely explains why monocytes, which preferentially use the proximal promoter, produce more protein than B cells do while producing a similar amount of total transcript (16) . However, there remain many questions regarding LILRB1 transcription such as how expression is regulated in different lymphoid lineages, why NK and T cells tend to have lower amounts of receptor on the cell surface than B cells do, as well as what initiates expression in only subsets of NK and T cells leading to the variegated expression pattern seen in these cell types? In order to understand the differential regulation of LILRB1 within lymphoid cell subsets and between individuals, we require a better knowledge of the factors involved in LILRB1 transcription.
In this study, we characterized regulatory regions and identified transcription factors involved in LILRB1 transcription, focusing on the distal promoter and expression in NK cells. We identified overlapping AP-1 sites within the core distal promoter that are required for maximal transcription in NK cells. We identified JunD as an AP-1 factor that not only occupies the region in the context of the native promoter but also enhances activity of this promoter when added exogenously. Additionally, we observed decreased expression of endogenous LILRB1 distal transcript when cellular JunD levels were decreased. Together, our results provide the first insight into the factors involved in transcription from the LILRB1 distal promoter as well as, to our knowledge, the first report of JunD regulating a gene in NK cells.
Methods

Cells and antibodies
THP-1 cells were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Sigma, Oakville, Ontario, Canada). YTS cells were cultured in Iscove's medium (Invitrogen) containing 15% FBS and supplemented with 50 µM 2-mercaptoethanol and glutamine (Invitrogen). NKL cells were cultured in Iscove's medium containing 10% characterized FBS (ThermoFisher Scientific, Ottawa, Canada). Cells (721.221) were cultured in Iscove's medium with 10% FBS, supplemented with glutamine. Studies performed with primary human cells were approved by the University of Alberta Health Research Ethics Board and blood was collected with informed consent from normal healthy donors as previously described (21) . PBMCs were isolated from whole blood using Lympholyte H (Cedarlane, Burlington, Ontario, Canada). B cells were isolated from PBMCs using the EasySep kit for human CD19 positive selection kit (StemCell Technologies, Vancouver, British Columbia, Canada). NK cells were isolated from the B-cell-depleted fraction or from PBMCs using an EasySep human NK cell enrichment kit (StemCell Technologies). For in vitro expansion, NK cells were isolated from PBMCs using the StemSep human NK cell enrichment kit (StemCell Technologies) and initially plated with irradiated 721.221 cells, 200 units ml −1 recombinant IL-2 (rIL-2) (Tecin, obtained from the National Cancer Institute) and 0.5 µg ml −1 phytohaemagglutinin (Sigma) in Iscove's medium with 10% human serum (Sigma). NK cells were propagated thereafter in Iscove's medium supplemented with 10% human serum, 2 mM glutamine and 200 U ml −1 of rIL-2. Cell purity and LILRB1 expression were examined at Day 1 (prior to plating), as well as before use in further experiments.
Anti-AML-1 (sc28679), anti-JunD (sc74), anti-Fos (sc271243) and anti-Fra2 (sc604) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-JunB (ab53543) was purchased from Abcam (Cambridge, MA, USA) and anticJun (39309) from Active Motif (Carlsbad, CA, USA). The IgG control antibody (CLAS10-916) was purchased from Cedarlane. PE-Cy5-labeled anti-LILRB1 antibody GHI/75 (551054) and an isotype control antibody (555744) were purchased from BD Biosciences (Mississauga, Ontario, Canada). Anti-CD56 and anti-CD3 (12-0569 and 555342), as well as isotype controls (12-4729 and 555576 respectively), were purchased from Ebiosciences (San Diego, CA, USA) and BD Biosciences.
Constructs and reporter assays
For use in reporter assays, fragments of the LILRB1 promoter regions were PCR amplified, with the addition of NheI and KpnI sites, from plasmids containing a larger region of the gene that was cloned from genomic DNA from donors with promoter sequences matching a reference sequence in Genbank (NC000019.9). The products were cloned into pCRII using the TOPO system (Invitrogen) and the entire sequence verified (MCLab, San Francisco, CA, USA) prior to sub-cloning into the luciferase vector, pGL3 basic (Promega, Madison, WI, USA). Deletions and point mutations were introduced using the Quikchange site-directed mutagenesis kit from Agilent Technologies (Santa Clara, CA, USA). Plasmids were prepared for transfection using endotoxin-free column purification (Qiagen, Mississauga, Ontario, Canada), and the concentration and purity were quantified using a Nanodrop (Thermo Fisher Scientific).
YTS cell nucleofections (AMAXA Biosystems, Gaithersburg, MD, USA) were performed with 5 × 10 6 cells/sample using KitR and program T-020 with 2 µg of pGL3 vector or equimolar amounts of the various constructs along with 10 ng of pRL-TK. NKL cell nucleofections were done the same way, except for the use of KitV and program O-017. For THP-1 cells, 1 × 10 6 cells were nucleofected using KitV and program V-001 with 0.4 µg pGL3 vector or the molar equivalent of each reporter plasmid and 10 ng pRL-TK. A parallel sample was transfected with a plasmid encoding enhanced GFP and analyzed by flow cytometry to ensure transfection efficiencies were in an acceptable range. Cells were incubated for 16 h before lysis in 250 μl of passive lysis buffer and analysis using the dual luciferase reporter assay kit (Promega). Samples were read in a 20/20n luminometer (Turner Biosystems, Sunnyvale, CA, USA). The transcriptional activity was normalized in each sample to the amount of renilla luciferase expression from the pRL-TK plasmid and expressed relative to a control sample transfected with an empty pGL3 basic vector. The JunD expression plasmid (pcDNA-JunD) and the empty control pcDNA vector were produced and generously provided by Dr Wilding (28) . For transactivation assays, luciferase assays were performed as above with the addition of 2.5 μg of pcDNA or pcDNA-JunD vector. These luciferase assays were harvested at 24 h post-transfection.
PCR
Total RNA was purified using the RNeasy kit and DNase treated on the column to remove genomic DNA (Qiagen). cDNA was synthesized using the qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD, USA). Primers and quantitative PCR methods used to amplify the long, total and RPL24 transcripts were described previously (18, 21) . Primers used to amplify the 'short' transcript are forward: 5′-CTG TGC TCG CTG CCA CAC GCA GCT CAG-3′ and reverse: 5′-GGG TGG GCT TGG GGA GGT GCC-3′. The PCR was performed using a touchdown program as follows: 95°C 3 min, 15× (30 s 95°C, 30 s t, 60 s 72°C) where in the first cycle t was 72°C and decreased by 1°C each cycle, 31× (30 s 95°C, 30 s 57°C, 60 s 72°C), 4 min 72°C. The specificity of the PCR was determined by sequencing of the PCR products. Products were run on a 2% agarose gel and visualized using ethidium bromide. For quantitative PCR, cDNA was synthesized using the qScript cDNA SuperMix and followed methods previously described (18) .
EMSAs
Double-stranded DNA probes were purchased from IDT Technologies (San Diego, CA, USA) and end-labeled with γ-[ 32 P] ATP using T4 polynucleotide kinase (New England Biolabs, Pickering, Ontario, Canada). To prepare nuclear extracts, cells were washed with PBS, re-suspended in 400 μl of freshly made cold Buffer A [10 mM HEPES pH 7.6, 10 mM KCl, 0.2% NP40, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulphonylfluoride (PMSF), 2 µg ml −1 aprotinin, 2 µg ml −1 leupeptin, 1 µg ml −1 pepstatin, 1 mM NaF and 1 mM NaV] and incubated on ice for 10 min. The nuclei were pelleted, washed with 1 ml of cold Buffer A and re-suspended in 20-80 µl of freshly made cold Buffer C (20 mM HEPES pH 7.9, 400 mM NaCl, 25% glycerol, 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 2 µg ml −1 aprotinin, 2 µg ml −1 leupeptin, 1 µg ml
pepstatin, 1 mM NaF and 1 mM NaV) and rotated for 30 min at 4°C. Nuclear debris was removed by centrifugation at 12 000 × g for 5 min and resulting supernatants aliquoted, snap-frozen and stored at −80°C. The protein concentration of the extracts was determined by bicinchoninic acid assay (Peirce, Rockford, IL, USA). For each EMSA reaction, nuclear extract corresponding to 5 µg of protein was incubated with ~2 ng of labeled probe in 4% glycerol, 50 ng µl −1 poly(dIdC), 50 mM NaCl, 10 mM Tris-HCl (pH 7.5), 0.5 mM EDTA and 1 mM MgCl 2 at room temperature for 20 min (adapted from ref. 29) . Where indicated, competitor probes were added at a 100-fold excess or antibodies at 1-2 µg per reaction (20 µl reaction volume) for 15 min at 4°C prior to incubation with the probe. The complexes were electrophoresed on a 5% native acrylamide gel at 20 mA for ~4 h in 0.5× Tris-Borate-EDTA (TBE) buffer at 4°C; the gel was dried and subjected to autoradiography. EMSA probe sequences are as follows (with the sense strand of the double-stranded DNA probe shown): 20 bp/3TF probe 5′-AGA AAT GAC TCA GTG GTG AG-3′ (with mutant forms shown in Fig. 3A ), probe 1 (−14 086 to −14 055) 5′-GCA TTT TGG GCC CTC CTG GAG GTG TTT AGA CC-3′, probe 2 (−14 054 to −14 022) 5′-TTC CGA GAG AGA AAC TGA GAC ACA TGA GAG GG-3′, probe 3 (−14 027 to −13 996) 5′-GAG GGA AGA AAT GAC TCA GTG GTG AGA CCC TG-3′ and probe 4 (−13 995 to −13 966) 5′-TGT GGA GTC CCA CCC ACA ACC AGC ACA CTG T-3′. The AP-1 consensus probe sequence was based on Asangani et al. (29) and the AML-1 consensus probe sequence on Meyers et al. (30) .
ChIP
NKL cells were re-suspended in fresh medium at 9 × 10 6 cells ml −1 in a total volume of 10 ml and fixed by addition of 270 µl of 37% formaldehyde (Fisher Scientific, Ottawa, Ontario, Canada) for 10 min at room temperature and then stopped by addition of 1 ml of 1.375 M glycine for 5 min. The cells were centrifuged at 600 × g for 5 min at 4°C, washed twice with 50 ml of cold PBS and lysed in 5 ml of cell lysis buffer [5 mM PIPES (pH 8.0), 85 mM KCl and 0.5% NP40] with protease inhibitor cocktail (PIC) (Sigma) on ice for 10 min. Nuclei were collected by centrifugation at 2500 × g for 5 min at 4°C, re-suspended in 500 µl of 1× micrococcal nuclease buffer and digested with 4 µl of micrococcal nuclease (New England Biolabs) for 15 min at 37°C and the reaction stopped with 50 µl of 0.5 M EDTA. The nuclei were pelleted again (as above), re-suspended in 1 ml of nuclear lysis buffer [50 mM Tris-HCl (pH 8), 10 mM EDTA and 1% SDS] with PIC and lysed on ice for 10 min followed by a brief sonication step (two 10-s pulses, 1 min apart at power 5) using the 60 sonic dismembrator (Fisher Scientific). The debris was removed by centrifugation. A sample was removed to ensure the average size range of the sheared DNA was between 200 and 1000 bp by heat treating to reverse cross-linking, purifying the DNA and analyzing on an agarose gel. The samples were precleared by addition of 50 µl of 'ChIP-blocked' protein G agarose beads from the EZ ChIP kit from Millipore (Billerica, MA, USA) and rotated for 1 h at 4°C. A 25 µl aliquot of sample was set aside as the 'input' control. The remaining supernatant was diluted with two volumes of ChIP dilution buffer [16.7 mM Tris-HCl (pH 8), 167 mM NaCl, 1.2 mM EDTA, 0.01% SDS and 1.1% Triton-X] and divided into equal aliquots before addition of 5 µg of rabbit IgG control or anti-JunD and incubation overnight at 4°C with rotation. The complexes were collected with 25 µl 'ChIP-blocked' protein G agarose beads for 2 h, washed three times with 1 ml of ChIP wash buffer [20 mM Tris-HCl (pH 8), 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS] for 5 min with agitation. A final wash was done with high salt ChIP wash buffer [20 mM Tris-HCl (pH 8), 500 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS]. The beads and the 'input DNA' sample were re-suspended in 300 µl of elution buffer (100 mM NaHCO 3 /1% SDS) for 15 min at room temperature. The supernatants were treated with 100 µg of proteinase K at 45°C for 1 h, followed by 65°C for 5 h to reverse the formaldehyde cross-linking. The DNA was purified from the reaction using a PCR purification kit (Qiagen) and eluted in 40 µl of water. PCR was performed using 5 µl of purified DNA with 0.4 μM primers using Taq polymerase (Invitrogen). The primers for the distal promoter were forward: 5′-GCA TTT TGG GCC CTC CTG GAG-3′ and reverse: 5′-AGC TGT GGG CTA GAG GTT TGT GCA-3′. Primers for the intron 1 PCR were forward: 5′-GCT TTA GGA ATT ACA TAG TTT CAG GT-3′ and reverse: 5′-ACA TAC TGA GCT TTG CTA AAG TCA A-3′. The PCR program included 34 cycles and an annealing temperature of 55°C. The PCR products were run on a 2% agarose gel and stained with ethidium bromide. For quantitative ChIP PCR, the same primers were used as above; however, a SYBR green master mix was used (Quanta Biosciences) with 1 µl of purified DNA. The calculation used was fold change = 2 
Small interfering RNA assays
NKL cells were transfected using the 4D nucleofector (AMAXA Biosystems). The nucelofections were performed with 2.5 × 10 6 cells/sample using program CM-150 and Kit L with the small interfering RNA (siRNA) at a concentration of 100 nM. Cells were nucleofected with either a pool of four siRNAs targeting JunD or a pool of four control siRNAs [Thermo Fisher Scientific (Dharmacon)]. JunD and LILRB1 transcripts were then quantified using quantitative PCR methods as described in the previous section on PCR, including an internal control transcript, RPL24. JunD was amplified using primers forward: 5′-TCC AGT CCA ACG GGC TGG TCA-3′ and reverse: 5′-GAC GAA GCC CTC GGC GAA CTC-3′.
Results
Characterization of active regulatory regions in NK cells
We have previously found activity from both the distal and proximal promoter regions using reporter assays in an NK-like cell line, YTS (18, 21) . Others have suggested that transcription from the distal promoter is more prevalent in NK cells (16) . Therefore, we tested the activity of these promoter constructs in a representative monocyte line as well as YTS and the LILRB1-expressing NK line, NKL. We again observed activity of both promoters in YTS cells, as well as in NKL and THP-1 cells (Fig. 1A) . The comparable activity of the two promoter constructs in all cells tested despite reports of lineagespecific promoter activity suggests that cell-type-specific regulation of endogenous promoter usage is likely subject to a level of epigenetic control.
Although we observed transcriptional activity of the proximal promoter in NK cell lines using reporter assays (Fig. 1A) (21) , there is no evidence to date that transcription from this promoter occurs in NK cells. To test this, we developed a PCR assay for the shorter transcript, using touchdown PCR to provide specificity due to the minimal amount of unique sequence in the short transcript (see Fig. 1B ). As expected, for sorted primary monocytes, we observed a substantial amount of product corresponding to the short transcript and the total message, but not the long transcript (Fig. 1C) . Again as expected, we detected the long transcript in purified NK cells, as well as cultured NK cells (Fig. 1C) . Although the true amounts of long and short transcript relative to one another cannot be discerned from this non-quantitative analysis, these results indicate the proximal promoter is used only minimally, if at all, by ex vivo NK cells (Fig. 1C) . However, these data do suggest a potential increase in transcription from the proximal promoter under culture conditions.
Given that we detect transcription from the distal promoter in ex vivo and cultured NK cells as well as NK cell lines, we wanted to further characterize which regions of this promoter are involved. Figure 2(A) illustrates the mapping of an active region between −14 086 and −13 965 using luciferase assays in YTS cells. This initial mapping was done prior to identification of the transcription start site for the distal promoter transcript of LILRB1 and the realization that an ATG in the exon causes a stuttering and thus, less efficient translation of the transcript (15) . In view of this, we also tested luciferase constructs using the transcriptional start as the 3′ end of the promoter fragments (Fig. 2B ). In agreement with Lamar et al. (16) , these constructs are more active in YTS cells than those with the first portion of exon 1 present; however, the core region of activity remains between −14 086 and −13 965 (Fig. 2B) .
To assess the ability of transcription factors to bind to the active region of the distal promoter, we performed EMSA using nuclear extracts from donor NK cells and probes that correspond to ~30-bp sections of the 120-bp active region (Fig. 2C ). Upon incubation of nuclear proteins from primary NK cells with probe 1, no complexes were evident (Fig. 2C) . Probe 2 produced two distinct complexes in NK cells, while probes 3 and 4 produced multiple distinct bands (Fig. 2C) . The location of the primers used in (C) is shown for the transcripts generated from the distal (long) and proximal (short) promoter regions as well as primers used to amplify the total message. (C) RNA was extracted from the cell types indicated above each lane. The transcripts were amplified using a touchdown PCR method as described in Methods and visualized in the gel by ethidium bromide. RPL24 was used as the control for RNA integrity between samples and the 293T cDNA was used as a negative control for amplification of LILRB1.
JunD activates LILRB1 transcription 25
A predicted AP-1 site is involved in transcriptional activity of the distal promoter
In the region corresponding to probe 3, there are multiple highly predicted transcription factor binding sites, including several overlapping AP-1/NFE2 sites and an AML-1 site (Fig. 3A) . Both AP-1 and AML-1 are expressed in lymphoid cells and thus are good candidates for involvement in regulation of transcription in NK cells. Therefore, we tested the effect of competitor oligos corresponding to optimal AP-1/NFE2 and AML-1 binding sites on factor binding to probe 3 by EMSA using nuclear extracts from the NKL cell line as well as primary NK cells. AP-1 and NFE2 have the same consensus binding sequence such that an AP-1 consensus sequence is also an NFE2 consensus sequence. The AP-1 consensus probe completely competed binding of both major species to probe 3, while competition with the AML-1 consensus probe shows only a slight decrease in the binding of factors to probe 3 and this decrease was inconsistent between experiments (Fig. 3B, left panel) . However, the presence of AML-1 in our extracts was confirmed using the AML-1 consensus oligo as a probe and an anti-AML-1 antibody (Fig. 3B , middle panel). While we were able to see a slight supershifted complex bound by probe 3 in the presence of the AML-1 antibody, mutation of the AML-1 site in probe 3 did not change the pattern of transcription factor binding.
A smaller 20-bp probe that contains the AP-1, NFE2 and AML-1 sites retained the ability to produce the complex with higher mobility seen with probe 3 (Fig. 3C, left panel) . The complex produced with the 20-bp fragment was competed by a 'self' competitor oligomer but not when the AP-1 site was mutated in that oligomer (mutation shown in Fig. 3A) , indicating the importance of this sequence for factor binding (Fig. 3C, right panel) . Also of note, the mutation used to eliminate the predicted AP-1 site also disrupts the less highly predicted MZF-1 and C/EBP sites. Additionally, the AP-1/ NFE2 mutated probe did not form any complexes when it was labeled and used as the probe with the same extracts (data not shown). The supershifted complex observed with the addition of AML-1 antibody is not present when the shorter 20-bp probe is used. Together, these results indicate that AP-1 (and/or NFE2), but not AML-1, is likely bound to the probe corresponding to the 20-bp region of the distal promoter.
To address the importance of the region containing the predicted AP-1/NFE2 sites for activity of the distal promoter, we generated luciferase constructs of the −14 086 to −13 793 region with the same mutations of the AP-1/NFE2 and AML-1 sites as were used for EMSA oligomers, as well as a 16-bp deletion that removes predicted binding sites for all three factors (see mutations and deletions in Fig. 3A) . While mutation of the AML-1 site reduced promoter activity by ~10%, both deletion of the whole region and point mutation of the AP-1/NFE2 sites led to an ~80% decrease compared with the activity of the wild-type construct (Fig. 3D) . These observations suggest that AP-1 likely mediates activity of the distal promoter, as there are no reports on expression of NFE2 in lymphocytes. The slight decrease in activity observed for the AML-1 mutation is likely due to a contribution of AML-1, as a small amount of complex is shifted by the AML-1 antibody with probe 3 (Fig. 3B) . Since several AP-1 factors are activated by phosphorylation by JNK, we examined the impact of inhibition of JNK on LILRB1 transcript levels. Treatment of NKL cells with an inhibitor of JNK, SP600125, led to a decrease in LILRB1 transcript compared with NKL cells treated with DMSO alone (Fig. 4) , supporting our observation that AP-1 factors may regulate LILRB1 transcription from the distal promoter.
Association of AP-1 factors with the distal promoter sequence
The AP-1 family of transcription factors includes cJun, JunB, JunD, cFos, FosB, Fra1 and Fra2, which can form homodimers or heterodimerize with other members of the family. To determine which, if any, of these factors associate with the 20-bp distal promoter probe, we tested binding by EMSA in the presence of anti-AP-1 antibodies. We observed a supershift of the complexes with four of the five AP-1 antibodies tested, although the relative amounts that shifted varied somewhat for extracts from cultured primary NK cells, NKL and YTS cell lines (Fig. 5A) . Supershift with anti-Fra2 in NKL and cultured NK cells varies from faint to undetectable in different experiments and different donors. Despite using two antibodies against cJun, one of which has been validated for ChIP, we observed no cJun binding ( Fig. 5 and data not shown) . This may be due to a lack of high levels of active cJun in NKL cells or could alternatively be due to a problem with the antibodies used. Also of note, the supershift observed in the presence of the JunD antibody was more complete and produced a larger sized complex (Fig. 5A ). This size difference could potentially be explained by the binding of more than one antibody molecule to the complex if it were composed of a JunD homodimer. The presence of at least three AP-1 family members in the shifted complex indicates there are likely several AP-1 complexes present in NK nuclei able to bind this DNA sequence. 
JunD-containing complexes in NK and B cells bind the distal promoter sequence
The presence of JunD in the binding complexes was particularly interesting in that, to our knowledge, there are no previous reports of JunD function in NK cells. To test if JunD is present in resting ex vivo NK cells and/or ex vivo B cells, we produced nuclear extracts from ex vivo NK and B cells isolated from PBMCs. For both extracts, the 20-bp probe formed a complex detected by EMSA that unlabeled self-competitor competed, while a competitor lacking the AP-1 site did not (Fig. 5B) . Addition of an anti-JunD antibody, but not an anticJun antibody, produced a supershift of the complex for both the NK and B-cell extracts, as well as cultured NK-cell extracts ( Fig. 5B and C) . Interestingly, the binding of factors, including JunD, to the promoter sequence appears enhanced with extracts from cultured versus ex vivo NK cells from the same donor (Fig. 5C ). These results indicate that JunD is present in the extracts of ex vivo and cultured NK cells, as well as B cells, and binds the promoter sequence in vitro.
To determine if JunD binds the native LILRB1 promoter, we performed a ChIP assay. We used NKL cells, in which the distal promoter is active (Fig. 1C) . We observed specific amplification of the region surrounding the predicted AP-1 site from the samples immunoprecipitated with anti-JunD compared with the control IgG and relative to primers for a region within intron 1 (Fig. 6) . These results indicate that JunD is bound to the LILRB1 distal promoter in the context of chromatin in cells where it is transcriptionally active.
JunD enhances LILRB1 distal promoter activity
JunD has been shown to have both activating and repressive effects on transcription. While the overlapping AP-1 sites are required for maximal activity of the promoter (see Fig. 3 ), implying an activating role for one or more AP-1 factors, this does not indicate the specific activity of JunD. Therefore, we employed transactivation assays using a JunD expression plasmid in conjunction with the distal LILRB1 promoter luciferase constructs in both a non-hematopoietic cell line (293T) and an NK cell line (YTS). Activity of the promoter was enhanced by addition of JunD in 293T (Fig. 7A) . In YTS cells, we observed an increase in promoter activity with the addition of JunD in each of the three assays included in Fig. 7(B) . However, this did not reach statistical significance when all assays were combined despite the trend being maintained within each experiment (empty pcDNA control:pcDNA JunD = 16.7:20.4, 18.5:24.4 and 19.7:36.6). In contrast to the enhanced activity of the wild-type promoter construct, activity of the promoter with the AP-1 site mutated was unaffected or very minimally altered in 293T and YTS, respectively.
In order to test the role of JunD on the endogenous LILRB1 distal promoter, we targeted JunD expression in NKL cells using siRNA. LILRB1 distal promoter transcript was decreased by an average of >35% in the presence of JunD siRNA compared with control siRNA (Fig. 7C) . Moreover, the decrease in LILRB1 transcript was well correlated with JunD knockdown efficiency as determined by quantitative PCR (Fig. 7C) .
Discussion
The factors that govern the usage of the two LILRB1 promoters in different cell types remain largely unknown. In the present study, we characterized the activity in NK cells of the two known promoter regions for LILRB1 and further mapped the regions involved in LILRB1 transcription from the distal promoter. Previous reports have defined a core region of the proximal promoter for transcription in monocytes and suggested that a PU.1 site in the core proximal promoter ~100 bp upstream of exon 2 is important (27) . In general, mature lymphocytes express much lower levels of PU.1 than myeloid cells do and this could explain why lymphoid cells require the distal promoter. While we detected activity of the proximal region in NK lines such as YTS and NKL by reporter assays, we did not detect transcripts originating from this promoter in ex vivo NK cells by PCR. This is in line with previous studies by us and others suggesting that the majority of the LILRB1 transcript detected in NK cells appears to arise from the distal promoter (16, 18, 21) . However, we did detect some short transcript in cultured NK cells. Our attempts to develop a copy number PCR method to properly quantify the amount of transcript from the proximal promoter were hampered by the nature of the limited unique region in the shorter transcript. It required a touchdown method to provide specificity for the PCR reactions, which is not quantitative. Therefore, the precise extent to which NK cells may use the proximal promoter remains unclear. The advantage of having the distal promoter remains unclear. It is possible the distal promoter is utilized as a means to limit the protein levels on the cell surface of lymphoid cells to tune down the signaling through LILRB1, as the transcript is not efficiently translated (16) . In relation to this, transgenic mice with a large genomic fragment encompassing the entire human LILRB1 gene, as well as flanking genes, uniformly express LILRB1 on all mouse NK cells at levels similar to B cells (31) . This is in contrast to human NK cells that express LILRB1 on a subset of cells and generally stain much dimmer than B cells. However, the analysis of the transgenic mouse predated discovery of the distal promoter and, therefore, which promoter was being used in the mice is not known (31) . Another possibility is that the two promoter system is involved during initial opening of the locus during development of NK cells by analogy with the KIR family that use a dual promoter system to initiate or silence the gene during development (32) (33) (34) (35) . Similar to the activity of the proximal region in NK cells, we also found that the distal promoter region can drive transcription in THP-1 cells indicating that the minimal necessary transcription factors are likely present in monocytes as well. However, we did not detect much RNA message arising from the distal promoter in purified monocytes (Fig. 1C) . Together, these results suggest that promoter preference in the different cell types likely arises to some extent from epigenetic regulation that limits or promotes accessibility of the promoter to the relative abundance of transcription factors available within different lineages/cell types. Here, we have shown transcripts arise from the distal LILRB1 promoter in NK cells and B cells, but not monocytes. We delineated a 120-bp region of the distal promoter that is required for optimal activity in NK cell lines and contains many predicted binding sites for transcription factors. We also found that the region binds several factors expressed by NK cells. The identity and relative importance of most of these factors for expression remains to be determined. Mutation of the predicted AP-1 sites reduced activity by 80%, indicating this site is highly important for the activity of the region. On the other hand, mutation of a predicted AML-1 site had only a modest effect. While we found evidence for only a slight AML-1 association with the sequence, several members of the AP-1 family of transcription factors did form complexes with the 20-bp probe containing the predicted AP-1 site. Together, these results suggest AP-1 is a major family of transcription factors involved in the activity of the core region of the distal promoter of LILRB1.
The AP-1 family includes the Jun (cJun, JunB and JunD), Fos (cFos, FosB, Fra1 and Fra2) and ATF (ATFa, ATF2 and ATF3) subfamilies. AP-1 factors form homo-or hetero-dimers and dimerization is required for DNA binding and transactivation of transcription. Many of the AP-1 family members are ubiquitously expressed but some are more restricted and regulated during growth and differentiation such that each cell type likely has its own unique mix of active AP-1 proteins. The target sequence in the LILRB1 distal promoter is a perfect consensus TGACTCA motif that typically binds Jun:Fos heterodimers. Therefore, it is not surprising that complexes containing AP-1 factors were able to bind the 20-bp probe encoding the LILRB1 AP-1 sites. Although AP-1 complexes are well known for their role in cell growth and the response to cell stress, AP-1 factors are also involved in regulating transcription of several receptors, signaling components and effector molecules within NK cells (36) (37) (38) (39) . For example, cJun, JunB and cFos regulate 2B4 expression (39) , cJun regulates DAP10 expression (40) and the promoters of Granzyme B and IFN-γ also involve AP-1 complexes (36, 37) . Curiously, we did not detect cJun binding to the LILRB1 AP-1 site with either of the antibodies tested. We did find Fos family members, including Fra2 as well as JunB and JunD, complexed with the LILRB1 AP-1 sequence. The failure to detect cJun with the probe may be due to low levels of cJun in our cells because while there is evidence that NKL cells do express cJun, it is not clear at what level active cJun protein is present (41) . Interestingly, JunD appears as a major component of the bound AP-1 complexes from NK and B cells as most of the complexes are shifted with anti-JunD antibodies. Additionally, we found JunD associated with the endogenous distal promoter in LILRB1 + NKL cells. Moreover, ectopic expression of JunD enhanced activity of the core promoter, while reduction of JunD levels led to a decrease in LILRB1 transcript from the endogenous promoter, suggesting that JunD-containing complexes stimulate, rather than repress, transcription. To our knowledge, this is the first report of JunD as a regulator of a gene in NK cells. JunD is not as well characterized as other AP-1 factors as it was the most recent member of the Jun family to be identified. Mice with JunD deleted are viable and the only phenotype in immune cells with JunD deficiency is hyperproliferation of lymphocytes upon mitogenic stimulation and altered cytokine production in T cells (42) (43) (44) . Therefore, JunD could be important for LILRB1 transcription in lymphocytes under various conditions. It might also be interesting to determine if differential expression or regulation of JunD in lymphocytes relative to myeloid lineage cells is involved in the opening of the distal promoter in lymphocytes.
AP-1 transcription factors can have activating or repressive roles and are subject to complex regulation through feedback on their own transcription and post-transcriptional modifications in response to signaling pathways including growth factors and cytokines (reviewed in ref. 45, 46) . Similar to other members of the AP-1 family, JunD is a target of the upstream kinases JNK and Erk that are activated in NK cells by a variety of stimuli including IL-2 and natural cytotoxicity receptors but in the case of JNK, this requires JunD to be in a heterodimer with another AP-1 family member to recruit the kinase (47, 48) . We observe a reduction of LILRB1 message when JNK is pharmacologically inhibited in the IL-2-dependent NK cell lymphoma line, NKL. Therefore, cytokine activation of NK cells may alter LILRB1 transcription via the AP-1 system. We previously reported that IL-2 and/or IL-15 treatment of ex vivo NK cells increases surface expression of LILRB1, but changes in mRNA were quite variable from one donor to the next (21) . The increase we observed in JunD-containing complex(s) binding to the LILRB1 AP-1 site when NK cells were differentiated in culture suggests there are either more complexes with JunD in the nuclear extracts able to bind the target due to increases in JunD protein or there might be changes in the levels of the binding partners of JunD and/or the phosphorylation of JunD or its partners, likely in response to signaling through IL-2.
In conclusion, we have characterized some of the DNA elements required for LILRB1 transcription in NK cells. We determined that the family of AP-1 transcription factors plays an activating role in transcription from the distal promoter and that the atypical AP-1 family member JunD is involved in this activation. In addition to cytokines, stimulation of NK cells through the natural cytotoxicity receptors also regulates expression of AP-1 family members (41) suggesting the net effects on a gene such as LILRB1 would be influenced by integration of many pathways during NK cell activation. Therefore, while questions remain such as whether other AP-1 family members are involved in transcription of LILRB1 and what events are involved in initiation of LILRB1 expression from the distal promoter in NK cells, these studies suggest a mechanism for how LILRB1 expression can be dynamically modulated in lymphocytes through the MAPK/AP-1 pathway. 
